. home.aspx

NEWS

home.aspx
   


US approves ViiV’s two-drug HIV regimen

November 22, 2017 / Selina McKee
SHARESHARESHARE

ViiV Healthcare’s Juluca has been green-lighted in the US as the first two-drug regimen for some patients with HIV. Juluca is comprised of ViiV’s dolutegravir, an integrase strand transfer inhibitor, and Janssen’s rilpivirine 25mg, a non-nucleoside reverse transcriptase inhibitor.